Combined Treatment Sofwave and Pure Impact to Strength and Tone Muscles and Improve Lax Skin Appearance
Launched by SOFWAVE MEDICAL LTD · Dec 4, 2024
Trial Information
Current as of June 10, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment that combines two methods, Sofwave and Pure Impact, to help improve the appearance of loose skin and strengthen muscles, specifically in the upper arms. It’s designed for adults aged 25 to 70 who have noticeable loose skin in that area and want to see improvements. Participants need to be in good health, not pregnant, and willing to commit to maintaining their weight during the study. They should also be free from certain medical conditions that could interfere with the treatment or healing process.
If you decide to participate, you’ll receive the combined treatment and have regular check-ins with the study team to monitor your progress. The trial is currently active but not recruiting new participants, so it’s important to keep that in mind. Additionally, participants agree not to use any other skin treatments for their upper arms for three months after completing the study. This trial aims to provide valuable information about how effective this combined treatment can be for improving skin laxity and muscle tone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female subjects ≥ 25 years of age and ≤ 70 years of age.
- • 2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
- • 3. Desire to undergo treatments on upper arms for skin lax and for strength and tone muscles.
- • 4. Subject has clearly visible lax skin on the upper arm, which in the investigator's opinion, may benefit from the treatment.
- • 5. Subject agrees to maintain his/her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the study.
- • 6. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
- • 7. Willing to have research photos taken of treatment areas.
- • 8. Subject agrees not to undergo any other upper arm skin lax treatments for a period of 3 months following SofWave and Pure Impact treatments.
- • 9. Able to understand and provide written Informed Consent.
- Exclusion Criteria:
- • 1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
- • 2. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, open wounds etc.) in the treatment area.
- • 3. Medical disorder that would hinder the wound healing or immune response (such as blood disorder) including but not limited to arterial circulation disorders in lower limbs, inflammatory disease, etc.
- • 4. Known allergy to lidocaine or epinephrine.
- • 5. Active malignancy or history of malignancy in the past 5 years.
- • 6. Suffering from significant concurrent illness, such as cardiac disorders, sensory disturbances, diabetes (type I or II), epilepsy, lupus, porphyria, pertinent neurological disorders, uncontrolled hypertension, or liver or kidney disease (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
- • 7. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- • 8. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
- • 9. History of significant lymphatic drainage problems.
- • 10. Currently a heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years.
- • 11. History of chronic drug or alcohol abuse.
- • 12. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
- • 13. BMI\>30kg/m2
- • 14. Non-stable weight nominally ±5% in the past month.
- • 15. Active implanted device such as a pacemaker, defibrillator, drug delivery system or any other metallic or electric implant anywhere in the body.
- • 16. Permanent implant in the treated area such as metal plates, screws and metal piercing, silicone implants or an injected chemical substance, unless deep enough in the periosteal plane.
- • 17. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
- • 18. History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.).
- • 19. History of prior surgery in the upper arms.
- • 20. Excessive subcutaneous fat on the upper arms.
- • 21. Severe solar elastosis on the intended to treat area.
- • 22. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising.
- • 23. Tattoo or former tattoo at or near treatment area.
- • 24. Muscle atrophy.
- • 25. Need for muscle rehabilitation.
- • 26. Persistent pain at the treated area.
- • 27. Any sensitivity for hydrogel (Pure Impact electrodes pads are made of hydrogel).
- • 28. History of ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep peeling within the past 12 months on the intended to treat area.
- • 29. Inability to understand the protocol or to give informed consent.
- • 30. Unable or unwilling to comply with the study requirements and procedures.
- • 31. Currently enrolled in a clinical study of any other unapproved investigational drug or device.
- • 32. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
About Sofwave Medical Ltd
Sofwave Medical Ltd. is an innovative medical technology company specializing in non-invasive aesthetic solutions. With a commitment to advancing skin rejuvenation and tightening, Sofwave leverages its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™) to deliver effective treatments that enhance patient outcomes with minimal downtime. The company is dedicated to conducting rigorous clinical trials that validate the safety and efficacy of its products, while continually striving to improve the patient experience and expand its portfolio of advanced therapeutic options in the field of dermatology and aesthetic medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported